v3.22.2.2
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)
12 Months Ended
Oct. 03, 2018
USD ($)
obligation
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
May 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from the issuance of common stock   $ 0 $ 0 $ 250,479,000  
Deferred revenue   74,099,000 111,055,000    
Revenues   243,231,000 138,287,000 $ 87,992,000  
Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Initial transaction price $ 252,700,000        
Janssen | Collaboration and License agreements          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Cash received as due under collaboration agreement 175,000,000        
JJDC | Common Stock Purchase Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Proceeds from the issuance of common stock 75,000,000        
Janssen          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payment 73,000,000        
Development, regulatory and sales milestones payments   4,900,000,000      
Janssen | License Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Development, regulatory and sales milestones payments 1,600,000,000        
Janssen | Collaboration Agreement | Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Development, regulatory and sales milestones payments 600,000,000        
Janssen | J N J3989 A R O H B V Agreement          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payment $ 25,000,000        
Number of distinct performance obligations | obligation 1        
Contract assets   0      
Deferred revenue   0      
Janssen | JNJ-75220795 (ARO-JNJ1)          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Milestone payment     10,000,000   $ 10,000,000
Contract assets   100,000      
Deferred revenue   0      
Revenues   $ 3,400,000 $ 500,000